Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Al­lo­gene CEO David Chang has com­plet­ed the up­beat first por­trait of the biotech’s off-the-shelf CAR-T con­tender AL­LO-501 at vir­tu­al AS­CO to­day, keep­ing all eyes on a drug that will now try to go on to re­place the first-wave per­son­al­ized pi­o­neers he helped cre­ate.

The over­all re­sponse rate out­lined in Al­lo­gene’s ab­stract for treat­ment-re­sis­tant pa­tients with non-Hodgkin lym­phoma slipped a lit­tle from the lead­up, but if you nar­row the pa­tient pro­file to treat­ment-naïve pa­tients — re­mov­ing the 3 who had pre­vi­ous CAR-T ther­a­py who didn’t re­spond, leav­ing 16 — the ORR lands at 75% with a 44% com­plete re­sponse rate. And 9 of the 12 re­spon­ders re­mained in re­sponse at the da­ta cut­off, of­fer­ing a glimpse on dura­bil­i­ty that still has a long way to go be­fore it can be com­plete­ly nailed down.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER